Senior Scientific LLC, a subsidiary of Manhattan Scientifics, Inc., is currently collaborating with The University of Texas MD Anderson Cancer Center (MDACC) to advance, demonstrate and validate a cancer detection and measurement technology originally developed by Edward R. Flynn, PhD. John D. Hazle, PhD of the MD Anderson Cancer Center recently presented initial results from the collaboration in a poster at the World Molecular Imaging Conference in Seoul, South Korea.
For the millions of sufferers of dry eye syndrome, their only recourse to easing the painful condition is to use drug-laced eye drops three times a day. Now, researchers from the University of Waterloo have developed a topical solution containing nanoparticles that will combat dry eye syndrome with only one application a week.
PharmaEngine Inc., a biopharmaceutical company developing new cancer treatments, and Nanobiotix S.A., a clinical-stage nanomedicine company pioneering in novel approaches for local treatment of cancer, announced today that the companies had strengthened their collaboration by jointly conducting a global pivotal trial of NBTXR3 in soft tissue sarcoma (STS) in Europe and Asia.
A proposal to develop a new way to remotely control brain cells from Sarah Stanley, a Research Associate in Rockefeller University’s Laboratory of Molecular Genetics, headed by Jeffrey M. Friedman, is among the first to receive funding from U.S. President Barack Obama’s BRAIN initiative. The project will make use of a technique called radiogenetics that combines the use of radio waves or magnetic fields with nanoparticles to turn neurons on or off.
A $1 million grant from the National Cancer Institute’s Small Business Innovation Research program will enable UCLA scientists and industry partners to take an innovative lung cancer treatment through the final steps toward its first clinical trial.
Avidity NanoMedicines today announced that it has expanded its investor syndicate through the closing of a $6 million convertible note financing co-led by Fidelity Biosciences and TPG Biotech.
Two years ago, Prof. Eshel Ben-Jacob of Tel Aviv University's School of Physics and Astronomy and Rice University's Center for Theoretical Biological Physics made the startling discovery that cancer, like an enemy hacker in cyberspace, targets the body's communication network to inflict widespread damage on the entire system.
NanoViricides, Inc. (the “Company”), a nanomedicine company developing anti-viral drugs, reported that its CEO, Eugene Seymour, MD, MPH, has been invited to discuss the current Ebola outbreak and the Company’s progress on a novel experimental Ebola drug on “The Independents”, a show on the Fox Business News Channel (FBN) tonight at 9PM EDT.
Liquidia Technologies today announced that it will highlight the transformative attributes of the company’s PRINT® (Particle Replication In Non-Wetting Templates) technology at the 12th International Nanomedicine and Drug Delivery Symposium (NanoDDS) in Chapel Hill, NC at the Carolina Club from October 6 – 8, 2014. NanoDDS is a key annual event for researchers developing next-generation delivery vehicles that can make diagnostics more sensitive and drugs more effective.
Nanoparticles have the potential to revolutionize the medical industry, but they must possess a few critical properties. First, they need to target a specific region, so that they do not scatter throughout the body. They also require some sort of sensing method, so that doctors and researchers can track the particles. Finally, they need to perform their function at the right moment, ideally in response to a stimulus.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.